EmbryoNet-AIEmbryoNet-AI
E

EmbryoNet-AI

AI platform for embryonic phenotyping that accelerates drug discovery and toxicology testing by automating analysis of embryos and organoids.

2025Active
Advertise here
About
EmbryoNet-AI is an ERC-funded research-to-commercialization project developing deep learning models for automated embryonic and organoid phenotyping. The platform enables faster, more accurate assessment of compound effects in drug discovery and toxicology studies, reducing dependence on animal models. The project is building a user-friendly web interface and collaborating with pharma partners to commercialize the technology.

Technology stack

detected 2026-05-23
Est. monthly stack spend~$70/mo
Emailunknown
Capital network
Open in Market Map editor
Frequently asked

What does EmbryoNet-AI do?

EmbryoNet-AI is an ERC-funded research-to-commercialization project developing deep learning models for automated embryonic and organoid phenotyping. The platform enables faster, more accurate assessment of compound effects in drug discovery and toxicology studies, reducing dependence on animal models. The project is building a user-friendly web interface and collaborating with pharma partners to commercialize the technology.

How much funding has EmbryoNet-AI raised?

EmbryoNet-AI has raised a total of $150K in funding. The most recent round on record is Grant.

Where is EmbryoNet-AI headquartered?

EmbryoNet-AI is headquartered in Lisbon, Portugal.

When was EmbryoNet-AI founded?

EmbryoNet-AI was founded in 2025.

What industry does EmbryoNet-AI operate in?

EmbryoNet-AI operates in Biotech, Drug Discovery, AI, Medical Imaging, Toxicology, Embryology.